Background
==========

Thyroid cancer is one of the most common types of endocrine malignancy, the incidence of which is increasing to be among the top malignancies in the United States \[[@b1-medscimonit-24-6438]\]. It is predicted that approximately 63 000 new cases of thyroid cancer were diagnosed in 2014 compared with 37 200 in 2009 \[[@b2-medscimonit-24-6438]\]. Anaplastic thyroid carcinoma (ATC), which accounts for about 1--2% of all thyroid carcinomas, is considered to be highly resistant to all therapies, with a 1-year survival rate of 5--30% \[[@b3-medscimonit-24-6438]\] and has a poor prognosis due to its extremely aggressive behavior \[[@b4-medscimonit-24-6438]\]. Accumulating evidence demonstrates the participation of multiple genes and cellular pathways in the occurrence and development of ATC. Understanding the molecular mechanism involved in proliferation, apoptosis, and invasion will greatly improve diagnosis and therapy. To date, however, little is known about the precise molecular mechanism underlying ATC progression.

In recent years, microarray technology, a high-throughput approach, has been widely used to profile gene expression \[[@b5-medscimonit-24-6438]\]. Many studies have made use of microarray technology to explore the differentially expressed genes (DEGs) in distinct pathways, biological processes, molecular functions, or cellular components \[[@b6-medscimonit-24-6438]--[@b8-medscimonit-24-6438]\]. Although current microarray technology has limited detection sensitivity and dynamic range, which restricts its ability to measure changes in low-level gene expression \[[@b9-medscimonit-24-6438]\], combining it with bioinformatics analysis enables comprehensive analysis of changes in expression of genes, providing a new and effective way to explore the molecular mechanisms of various cancers \[[@b10-medscimonit-24-6438]--[@b12-medscimonit-24-6438]\]. However, a reliable and accurate result with respect to ATC is still lacking.

Therefore, in this study, we aimed to identify the key pathways and genes in ATC with the aid of extensive bioinformatics methods. We obtained 3 mRNA expression profile data sets - GSE9115, GSE65144, and GSE53072 -- to conduct collaborative microarray analysis. The DEGs were first screened between ATC tissues and normal tissues for each data set. Then, the common DEGs from these 3 data sets were selected for gene ontology (GO) and pathway enrichment analysis, followed by protein--protein interaction (PPI) network construction and module analysis. Our results provide further insights into the development of ATC at the molecular level and reveal potential diagnostic biomarkers and therapeutical targets for ATC.

Material and Methods
====================

Microarray data
---------------

We obtained 3 gene expression profiles (GSE9115, GSE65144, and GSE53072) from the Gene Expression Omnibus (GEO, *<http://www.ncbi.nlm.nih.gov/geo>*), which is a public repository of gene expression datasets, original series, and platform records. The array data of GSE9115 includes 4 normal thyroid samples and 5 ATC samples \[[@b13-medscimonit-24-6438]\]. GSE65144 consists of 13 normal thyroid samples and 12 ATC samples \[[@b14-medscimonit-24-6438]\]. GSE53072 contains 4 normal thyroid samples and 5 ATC samples \[[@b15-medscimonit-24-6438]\].

Identification of DEGs
----------------------

We used statistical analysis software R (version 3.5.0, *<https://www.r-project.org/>*) and packages of Bioconductor (*<http://www.bioconductor.org/>*) to conduct significance analysis of DEGs between ATC samples and normal samples among the 3 data sets, respectively. The microarray data were first pre-processed using the algorithm "RMA", which contains background adjustment and normalization with quantile method. Then, the Moderated T statistic approach was used to select significant DEGs with the „limma" package of Bioconductor. Finally, DEGs were annotated through an annotation table downloaded from the GEO website. The *P* value \<0.05 and \|logFC\| \>1 were set as the cutoff criteria. The common DEGs from the 3 gene expression datasets were extracted via the online tool Venny 2.1 (*<http://bioinfogp.cnb.csic.es/tools/venny/index.html>*) and used for the following analyses. The heat maps of the common DEGs for each data set were constructed using the Morpheus online tool (*<https://software.broadinstitute.org/morpheus/>*).

Functional and pathway enrichment analysis
------------------------------------------

Gene ontology (GO, *<http://www.geneontology.org/>*) is a framework for the model of biology, which describes gene functions and classifies them along 3 aspects: molecular function (MF), cellular component (CC), and biological process (BP). The Kyoto Encyclopedia of Genes and Genomes (KEGG, *<http://www.genome.jp/kegg/>*) is a collection of databases for understanding high-level gene functions and utilities of the biological system. The Database for Annotation, Visualization, and Integrated Discovery (DAVID, *<https://david.ncifcrf.gov/home.jsp>*) is an online tool that provides a comprehensive set of functional annotation tools to investigate the biological meaning behind a mass of genes. In order to analyze DEGs at the functional level, GO term enrichment analysis and KEGG pathway enrichment analysis were conducted using DAVID. P\<0.05 was considered to have statistical significance and to achieve significant enrichment.

PPI network construction and modules analysis
---------------------------------------------

The Search Tool for the Retrieval of Interacting Genes (STRING, *<https://string-db.org/>*) is a freely accessible biological database to evaluate protein--protein interaction information. STRING (version 10) contains 9 643 763 proteins from 2031 organisms. To assess the interactive relationships among DEGs, the DEGs were mapped to STRING with the confidence score \>0.7 set as the cutoff criterion. Then, the PPI network was constructed and visualized using Cytoscape. The plug-in Molecular Complex Detection (MCODE) \[[@b16-medscimonit-24-6438]\] was used to screen the modules of the PPI network with the following criteria: Max. Depth=100, K-Core=2, Mode Score Cutoff=0.2, and Degree Cutoff=2. Moreover, the function and pathway enrichment analysis were conducted for DEGs in each module with the plug-in Biological Network Gene Ontology (BiNGO). P\<0.05 was considered to indicate significant differences.

Results
=======

Identification of DEGs
----------------------

A total of 3214, 3553, and 1884 DEGs were identified from GSE53072, GSE65144, and GSE9115, respectively, and a total of 537 DEGs were screened out from all 3 datasets as shown in [Figure 1C](#f1-medscimonit-24-6438){ref-type="fig"}. Among them, 247 genes were upregulated and 275 genes were downregulated ([Figure 1A, 1B](#f1-medscimonit-24-6438){ref-type="fig"}). The hierarchical clustering analysis of 537 overlapped DEGs in the 3 datasets is shown in [Figure 2](#f2-medscimonit-24-6438){ref-type="fig"}. As shown in the expression heat maps, there were significant differences between the ATC group and the normal control group in expression patterns of DEGs. The results indicated the high consistency in expression patterns of DEGs among the 3 datasets, and that the overlapped DEGs may be truly differentially expressed in the ATC group compared with those in the normal control group.

GO term enrichment analysis
---------------------------

The common identified DEGs, including both upregulated and downregulated ones, were all uploaded to DAVID to identify overrepresented GO categories and KEGG pathways. The upregulated DEGs were mainly involved in biological process (BP), associated with cell division, mitotic nuclear division, and cell adhesion, and the downregulated DEGs were significantly enriched in melanocyte differentiation, regulation of phosphatidylinositol 3-kinase signaling, and ventricular cardiac muscle cell action potential ([Table 1](#t1-medscimonit-24-6438){ref-type="table"}). In the cell component (CC) ontology, the upregulated DEGs were enriched in kinetochore, extracellular space, and membrane, and the downregulated DEGs were enriched in extracellular exosome, apical plasma membrane, and sarcolemma. Molecular function (MF) analysis also indicated that the upregulated DEGs were significantly enriched in protein binding, ATP binding, and integrin binding, and the downregulated DEGs were enriched in calmodulin binding, oxidoreductase activity, and acyl-CoA dehydrogenase activity.

KEGG pathway analysis
---------------------

To gain further insight into the function of the identified DEGs, [Table 2](#t2-medscimonit-24-6438){ref-type="table"} shows the top 10 significantly enriched pathways of the upregulated DEGs and downregulated DEGs through KEGG analysis. The upregulated DEGs were mainly enriched in cell cycle, ECM-receptor interaction, and leishmaniasis, and the downregulated DEGs were mainly enriched in thyroid hormone synthesis, insulin resistance, and pathways in cancer.

PPI network construction and module selection
---------------------------------------------

Based on 537 DEGs, \|logFC\|\>2 is individually set as the cutoff criteria to present a clear PPI network ([Figure 3](#f3-medscimonit-24-6438){ref-type="fig"}). Based on information from the STRING database, the top 10 DEGs with higher degrees were screened and selected as hub genes, which showed a strong association with other node proteins, as depicted in [Figure 4](#f4-medscimonit-24-6438){ref-type="fig"}. Among these hub genes, CDK1 showed the highest node degree, which was 113. In addition, the top 2 most significant modules were selected ([Figure 5](#f5-medscimonit-24-6438){ref-type="fig"}), and the enrichment analysis ([Tables 3](#t3-medscimonit-24-6438){ref-type="table"}, [4](#t4-medscimonit-24-6438){ref-type="table"}) showed that the genes in these 2 modules were mainly associated with cell cycle and positive regulation of mitosis, respectively.

Discussion
==========

Anaplastic thyroid cancer (ATC) remains one of the deadest diseases. Recent studies showed that mutations, amplifications, activation of oncogenes, and silencing of tumor suppressor genes contribute to its aggressive behavior \[[@b17-medscimonit-24-6438]\]. Understanding the etiological factors and molecular mechanism of ATC is of critical importance to improving its survival rate and prevention. Due to the rapid development of microarray technologies in recent years, we are able to explore the potential targets for diagnosis, therapy, and prognosis of ATC via integrated bioinformatic methods.

In this study, 3 gene expression data sets of ATC were retrieved from the GEO data set. A total of 537 DEGs were screened, including 247 upregulated genes and 275 downregulated genes. In order to investigate the biological meaning behind these DEGs, we performed GO and KEGG pathway analysis.

The bioinformatics analysis showed that these upregulated genes were mainly related to cell proliferation. Specifically, GO term enrichment analysis showed that 29 upregulated DEGs participated in cell division and 20 upregulated DEGs enriched in mitotic nuclear division. KEGG pathway analysis indicated that 14 upregulated DEGs were significantly enriched in cell cycle and 5 upregulated DEGs were enriched in DNA replication. PPI network and module analysis also indicated that the gene modules were significantly enriched in cell proliferation. It has been shown that uncontrolled cell proliferation is the primary feature of cancer, and tumor cells can damage genes that directly regulate their cell cycles \[[@b18-medscimonit-24-6438]\]. The role of the cell cycle is believed to be important in the etiology of cancer \[[@b19-medscimonit-24-6438]\]. The present study clearly shows that many DEGs influenced the development of ATC by regulating cell proliferation. For example, CDCA4, a member of the CDCA family, which was upregulated in our study, participates in regulation of proliferation through the E2F/retinoblastoma pathway \[[@b20-medscimonit-24-6438]\]. In addition, as the main upregulated DEGs, kinesin superfamily proteins (KIFs) are essential for cell mitosis and meiosis, the abnormality of which can cause cell death, gene deletion, and even carcinogenesis \[[@b21-medscimonit-24-6438]\]. Therefore, it is meaningful to further explore the relationships and mechanisms between the DEGs and ATC.

GO term enrichment analysis also suggested that several downregulated genes participated in the development of thyroid carcinoma, as 4 genes were enriched in ventricular cardiac muscle cell action potential. Specifically, the first published GWAS in differentiated thyroid cancer confirmed the association with the 3p22 SNP rs1159444 c(GPD1L) \[[@b22-medscimonit-24-6438]\]. In addition, the other 3 downregulated genes in ventricular cardiac muscle cell action potential have been confirmed to play roles in thyroid cancer \[[@b23-medscimonit-24-6438],[@b24-medscimonit-24-6438]\], but the exact mechanism is still unknown. Furthermore, KEGG pathway analysis demonstrated that downregulated DEGs are mainly involved in insulin resistance (IR) and pathways in cancer. This is consistent with data showing that high prevalence of IR is an important risk factor for thyroid cancer \[[@b25-medscimonit-24-6438]\], and that the variant signaling pathway participates in thyroid cancer \[[@b26-medscimonit-24-6438]\]. Hayashi et al. \[[@b27-medscimonit-24-6438]\] reported the antitumor effects of peroxisome proliferator activate receptor γ ligands on anaplastic thyroid carcinoma, which has been regarded as a target for insulin resistance type 2 diabetes treatment. The enriched DEGs analyzed by the KEGG pathway are mainly involved in the PI3K-AKT signaling pathway, the MAPK signaling pathway, and the wnt signaling pathway. In previous studies, the PI3K-AKT and MAPK signaling pathways were shown to be primarily involved in FTC and differentiated PTC, respectively \[[@b28-medscimonit-24-6438],[@b29-medscimonit-24-6438]\]. A growing number of studies have demonstrated that the dual activation of MAPK and PI3K-AKT pathways may be a common mechanism for promoting the progression of thyroid cancer \[[@b30-medscimonit-24-6438]\]. Furthermore, Kurihara et al. have identified the association of the wnt signaling pathway with anaplastic thyroid cancer \[[@b31-medscimonit-24-6438]\]. Hence, the molecular-targeting therapy of ATC needs to be further explored in future studies.

The PPI network was constructed among 569 DEGs and presented the top 10 hub genes: CDK1, CCNB1, TOP2A, AURKB, CCNA2, BUB1, AURKA, CDC20, MAD2L1, and BUB1B. CDK1 has the highest degree of node connectivity in the PPI network; it plays an important role in unrestricted cell proliferation and regulates the cell cycle, mainly by interacting with cell cycle regulatory cyclins. For example, the CDK1-cyclin B1 complex is responsible for entry and progression of the mitotic phase (M) \[[@b32-medscimonit-24-6438],[@b33-medscimonit-24-6438]\]. By inhibiting the activity of CDK1, the proliferation of thyroid cancer can be repressed *in vivo* and *in vitro* \[[@b34-medscimonit-24-6438]\]. The second and the fifth hub genes, CCNB1 and CCNA2, belong to the highly conserved cyclin family. CCNB1 complexes with p43 (cdc2) to form the maturation-promoting factor (MPF) and plays vital roles in control of the cell cycle at G2/M transitions, while CCNA2 is involved in control of the cell cycle at the G1/S and the G2/M transitions and is necessary in embryonic cells and hematopoietic lineage. Both of them have been reported to be expressed in many cancer types \[[@b35-medscimonit-24-6438],[@b36-medscimonit-24-6438]\]. Accumulating evidence shows that CCNB1 is overexpressed in 4 undifferentiated thyroid carcinomas \[[@b37-medscimonit-24-6438]\] and ATC is overexpressed in genes that code for cyclins, including CCNA2 \[[@b13-medscimonit-24-6438]\]. The third hub gene TOP2A is located on chromosome 17q12-q21 near the HER2 oncogene. It is well known that co-amplification of HER2 and TOP2A is associated with sensitivity to anthracycline therapy for some types of cancer \[[@b38-medscimonit-24-6438]\]. Some recent studies also reported that TOP2A is upregulated in the ATC and cell lines and is involved in DNA replication and DNA metabolic processes \[[@b39-medscimonit-24-6438]\]. As a member of the Aurora kinases family, AURKA is an important protein in the regulation of G2/M transition during mitosis. It has been identified that AURKA is one of the most frequently and strongly overexpressed genes in some tumors, including ATC \[[@b40-medscimonit-24-6438]\]. Another Aurora kinase, AURKB, has a dynamic subcellular localization during cell cycle progression. It was shown that overexpression of AURKB can lead to multinucleation and polyploidy and is highly correlated with genomic instability and poor prognosis in thyroid cancers, indicating its role in neoplastic transformation \[[@b41-medscimonit-24-6438]\].

BUB1 is a multi-task protein kinase required for proper chromosome segregation in eukaryotes. Quyang et al. \[[@b42-medscimonit-24-6438]\] demonstrated that no mutations of BUB1 exist in the thyroid carcinoma cell lines and that other factors must account for the mitotic checkpoint dysfunction and chromosomal instability detected in thyroid cancer cells. In contrast, a recent study showed that the high expression of BUB1B, which originated from the same gene of BUB1, was associated with recurrence in papillary thyroid cancer \[[@b43-medscimonit-24-6438]\]. Therefore, more studies are needed to investigate the function of BUB1 and BUB1B in ATC. The interaction between BUB1 and BUB1B in ATC needs to be explored as well. As an important factor of the spindle assembly checkpoint, CDC20 plays a crucial role in tumorigenesis and progression. Recent studies showed that CDC20 expression was ATC-specifically upregulated \[[@b44-medscimonit-24-6438]\]. It has also been shown that disruption of MAD2L1, an important interactive protein in maintaining spindle checkpoint function, is closely associated with aneuploidy and tumorigenesis \[[@b45-medscimonit-24-6438]\]. However, further studies are needed to determine the role of MAD2L1 in ATC.

Conclusions
===========

In conclusion, we used a series of bioinformatics analysis methods to identify the key genes and pathways involved in ATC initiation and progression from 3 gene expression profiles containing normal samples and ATC samples. Our results provide a more detailed molecular mechanism for the development of ATC, shedding light on the potential biomarkers and therapeutic targets. However, the interacting mechanism and function of genes need to be confirmed in further experiments.
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###### 

Gene ontology analysis of differentially expressed genes associated with anaplastic thyroid cancer.

  Category            Term                                                                                                   Count   \%            P value
  ------------------- ------------------------------------------------------------------------------------------------------ ------- ------------- -------------
  **Upregulated**                                                                                                                                  
  GOTERM_BP_DIRECT    GO: 0051301\~cell division                                                                             29      0.073774454   8.89E-14
  GOTERM_BP_DIRECT    GO: 0007067\~mitotic nuclear division                                                                  20      0.050878934   2.14E-09
  GOTERM_BP_DIRECT    GO: 0007155\~cell adhesion                                                                             24      0.06105472    1.32E-07
  GOTERM_BP_DIRECT    GO: 0007229\~integrin-mediated signaling pathway                                                       12      0.03052736    1.36E-07
  GOTERM_BP_DIRECT    GO: 0000082\~G1/S transition of mitotic cell cycle                                                     12      0.03052736    1.86E-07
  GOTERM_CC_DIRECT    GO: 0000776\~kinetochore                                                                               12      0.03052736    9.65E-09
  GOTERM_CC_DIRECT    GO: 0016020\~membrane                                                                                  56      0.142461014   2.23E-06
  GOTERM_CC_DIRECT    GO: 0005615\~extracellular space                                                                       40      0.101757867   3.20E-06
  GOTERM_CC_DIRECT    GO: 0005925\~focal adhesion                                                                            18      0.04579104    1.99E-05
  GOTERM_CC_DIRECT    GO: 0000777\~condensed chromosome kinetochore                                                          9       0.02289552    2.04E-05
  GOTERM_MF_DIRECT    GO: 0005515\~protein binding                                                                           160     0.407031469   2.37E-06
  GOTERM_MF_DIRECT    GO: 0005524\~ATP binding                                                                               42      0.106845761   2.64E-05
  GOTERM_MF_DIRECT    GO: 0005178\~integrin binding                                                                          9       0.02289552    1.19E-04
  GOTERM_MF_DIRECT    GO: 0005518\~collagen binding                                                                          7       0.017807627   1.95E-04
  GOTERM_MF_DIRECT    GO: 0004872\~receptor activity                                                                         12      0.03052736    2.65E-04
  **Downregulated**                                                                                                                                
  GOTERM_BP_DIRECT    GO: 0086005\~ventricular cardiac muscle cell action potential                                          4       0.011480265   2.30E-04
  GOTERM_BP_DIRECT    GO: 0014066\~regulation of phosphatidylinositol 3-kinase signaling                                     7       0.016072372   0.00136878
  GOTERM_BP_DIRECT    GO: 0030318\~melanocyte differentiation                                                                5       0.009184212   0.001486948
  GOTERM_BP_DIRECT    GO: 0033539\~fatty acid beta-oxidation using acyl-CoA dehydrogenase                                    4       0.009184212   0.002576085
  GOTERM_BP_DIRECT    GO: 0009083\~branched-chain amino acid catabolic process                                               4       0.009184212   0.003024104
  GOTERM_CC_DIRECT    GO: 0070062\~extracellular exosome                                                                     77      0.176796088   9.63E-08
  GOTERM_CC_DIRECT    GO: 0016324\~apical plasma membrane                                                                    16      0.036736849   3.52E-05
  GOTERM_CC_DIRECT    GO: 0042383\~sarcolemma                                                                                8       0.018368425   2.86E-04
  GOTERM_CC_DIRECT    GO: 0016323\~basolateral plasma membrane                                                               11      0.025256584   3.96E-04
  GOTERM_CC_DIRECT    GO: 0005856\~cytoskeleton                                                                              16      0.036736849   5.10E-04
  GOTERM_MF_DIRECT    GO: 0005516\~calmodulin binding                                                                        12      0.027552637   1.40E-04
  GOTERM_MF_DIRECT    GO: 0052890\~oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor   4       0.009184212   0.001339754
  GOTERM_MF_DIRECT    GO: 0005200\~structural constituent of cytoskeleton                                                    8       0.018368425   0.001372584
  GOTERM_MF_DIRECT    GO: 0003995\~acyl-CoA dehydrogenase activity                                                           4       0.009184212   0.001630695
  GOTERM_MF_DIRECT    GO: 0044325\~ion channel binding                                                                       7       0.016072372   0.007246827

###### 

The top 10 enriched KEGG pathways of differentially expressed genes associated with anaplastic thyroid cancer.

  Pathway ID/Name                                       Count   \%            P Value       Genes
  ----------------------------------------------------- ------- ------------- ------------- ------------------------------------------------------------------------------------------------------------
  **Upregulated DEGs**                                                                      
  hsa04110: Cell cycle                                  14      0.035615254   6.15E-07      CDC7, CDC6, MAD2L1, CCNB2, YWHAH, BUB1, TTK, BUB1B, CHEK1, CCNA2, MCM4, MYC, MCM5, MCM6
  hsa04512: ECM-receptor interaction                    9       0.02289552    2.49E-04      COL3A1, ITGB5, ITGA2, ITGA4, ITGB1, COL5A1, SPP1, FN1, HMMR
  hsa05140: Leishmaniasis                               8       0.020351573   3.99E-04      IRAK1, MYD88, TLR2, FCGR2A, ITGA4, STAT1, ITGB1, ITGAM
  hsa05205: Proteoglycans in cancer                     12      0.03052736    0.001565479   CASP3, HPSE, MMP9, TLR2, ITGB5, ITGA2, MYC, ITGB1, PLAU, FN1, TWIST1, PLAUR
  hsa04151: PI3K-Akt signaling pathway                  16      0.040703147   0.002476592   IL2RA, COL3A1, TLR2, ITGB5, ITGA2, ITGA4, ITGB1, COL5A1, EIF4EBP1, YWHAH, IL4R, MYC, SPP1, FN1, CSF1R, F2R
  hsa04145: Phagosome                                   10      0.025439467   0.00265876    CYBB, FCGR2B, TLR2, ITGB5, ITGA2, FCGR2A, CTSS, TUBA1A, ITGB1, ITGAM
  hsa04611: Platelet activation                         9       0.02289552    0.003464929   ADCY7, COL3A1, ITGA2, FCGR2A, ITGB1, VASP, COL5A1, LCP2, F2R
  hsa04380: Osteoclast differentiation                  9       0.02289552    0.003631749   CYBB, FCGR2B, LILRB4, FCGR2A, TREM2, STAT1, CSF1R, LCP2, TYROBP
  hsa03030: DNA replication                             5       0.012719733   0.004794752   POLE2, MCM4, MCM5, FEN1, MCM6
  hsa04666: Fc gamma R-mediated phagocytosis            7       0.017807627   0.00540983    ARPC1B, FCGR2B, RAC2, HCK, WASF1, FCGR2A, VASP
  **Downregulated DEGs**                                                                    
  hsa04918: Thyroid hormone synthesis                   7       0.016072372   0.001859153   SLC26A4, PLCB4, ADCY9, PAX8, ATP1A1, LRP2, ITPR1
  hsa05202: Transcriptional misregulation in cancer     9       0.020664478   0.013054046   HHEX, NUPR1, ID2, CCND2, PAX8, ARNT2, TSPAN7, PBX1, MLLT3
  hsa04931: Insulin resistance                          7       0.016072372   0.015302523   PRKCQ, PIK3CB, RPS6KA2, TBC1D4, IRS1, PPARGC1A, SLC27A2
  hsa04015: Rap1 signaling pathway                      10      0.022960531   0.016414205   FGFR2, PLCB4, MAGI1, ADCY9, PIK3CB, EFNA1, VEGFA, CDH1, KIT, RAPGEF3
  hsa04972: Pancreatic secretion                        6       0.013776319   0.02955826    PLCB4, ADCY9, RYR2, ATP1A1, SLC4A4, ITPR1
  hsa05200: Pathways in cancer                          14      0.032144743   0.031228341   FGFR2, PIK3CB, ARNT2, FZD3, CDH1, KIT, DAPK2, EDNRB, FOS, PLCB4, ADCY9, BCL2, PAX8, VEGFA
  hsa04960: Aldosterone-regulated sodium reabsorption   4       0.009184212   0.035652255   PIK3CB, ATP1A1, SCNN1A, IRS1
  hsa04020: Calcium signaling pathway                   8       0.018368425   0.049708184   EDNRB, GNAL, PLCB4, ADCY9, ERBB3, PDE1A, RYR2, ITPR1

###### 

GO enrichment analysis of module 1 from the protein--protein interaction network.

  GO-ID   p Value    Description                             Genes in test set
  ------- ---------- --------------------------------------- ----------------------------------------------------
  278     1.82E-08   Mitotic cell cycle                      CDC20\|CDC45\|NUF2\|CDK1\|MCM10\|BUB1\|NDC80
  22402   1.84E-08   Cell cycle process                      CDC20\|CDC45\|EXO1\|NUF2\|CDK1\|MCM10\|BUB1\|NDC80
  7049    6.68E-08   Cell cycle                              CDC20\|CDC45\|EXO1\|NUF2\|CDK1\|MCM10\|BUB1\|NDC80
  22403   1.76E-07   Cell cycle phase                        CDC20\|CDC45\|NUF2\|CDK1\|MCM10\|BUB1\|NDC80
  7067    2.29E-06   Mitosis                                 CDC20\|NUF2\|CDK1\|BUB1\|NDC80
  87      2.41E-06   M phase of mitotic cell cycle           CDC20\|NUF2\|CDK1\|BUB1\|NDC80
  280     2.98E-06   Nuclear division                        CDC20\|NUF2\|CDK1\|BUB1\|NDC80
  48285   3.84E-06   Organelle fission                       CDC20\|NUF2\|CDK1\|BUB1\|NDC80
  226     9.12E-06   Microtubule cytoskeleton organization   CDC20\|NUF2\|BUB1\|NDC80
  7017    1.60E-05   Microtubule-based process               CDC20\|NUF2\|BUB1\|NDC80
  45787   3.91E-05   Positive regulation of cell cycle       CDC20\|CDK1

###### 

GO enrichment analysis of module 2 from the protein--protein interaction network.

  GO-ID   p Value    Description                                                                               Genes in test set
  ------- ---------- ----------------------------------------------------------------------------------------- -------------------
  45840   3.22E-04   Positive regulation of mitosis                                                            CDH1
  45842   3.22E-04   Positive regulation of mitotic metaphase/anaphase transition                              CDH1
  51488   3.22E-04   Activation of anaphase-promoting complex activity                                         CDH1
  45862   3.22E-04   Positive regulation of proteolysis                                                        CDH1
  51785   3.22E-04   Positive regulation of nuclear division                                                   CDH1
  32436   3.22E-04   Positive regulation of proteasomal ubiquitin-dependent protein catabolic process          CDH1
  7092    3.22E-04   Activation of mitotic anaphase-promoting complex activity                                 CDH1
  10697   3.22E-04   Negative regulation of spindle pole body separation                                       CDH1
  51437   3.22E-04   Positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle   CDH1
  32434   4.83E-04   Regulation of proteasomal ubiquitin-dependent protein catabolic process                   CDH1
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